Epidermal growth factor induces cell death in the absence of overexpressed epidermal growth factor receptor and erbb2 in various human cancer cell lines

Cancer Investigation

Volumn 28, Issue 5, 2010, Pages 505-514

  Choi, Jene ^a   Moon, Soo Young ^a   Hong, Joon Pio ^a   Song, Ji Young ^a   Oh, Kyung Taek ^a   Lee, Sang Wook ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Apoptosis; Epidermal growth factor (EGF); Epidermal growth factor receptor (EGFR); ErbB2

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FRACIS; NEPIDERMIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CELL LINE; CELL PROLIFERATION; CELL STRAIN 293T; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; CASPASES; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952167585     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357900902783179     Document Type: Article

References (37)

1. Singh, A.B.; Harris, R.C. Autocrine, paracrine and juxtacrine signaling by EGFR ligands. Cell Signal 2005, 17(10), 1183-1193.
2. Witton, C.J.; Reeves, J.R.; Going, J.J.; Cooke, T.G.; Bartlett, J.M. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003, 200(3), 290-297.
3. Hirsch, F.R.; Varella-Garcia, M.; Bunn, P.A. Jr.; Di Maria, M.V.; Veve, R.; Bremmes, R.M.; Bar ́on, A.E.; Zeng, C.; Franklin, W.A. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21(20), 3798-3807.
4. Chung, C.H.; Ely, K.; McGavran, L.; Varella-Garcia, M.; Parker, J.; Parker, N.; Jarrett, C.; Carter, J.; Murphy, B.A.; Netterville, J.; Burkey, B.B.; Sinard, R.; Cmelak, A.; Levy, S.; Yarbrough, W.G.; Slebos, R.J.; Hirsch, F.R. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol 2006, 24(25), 4170-4176.
5. Stadlmann, S.; Gueth, U.; Reiser, U.; Diener, P.A.; Zeimet, A.G.; Wight, E.; Mirlacher, M.; Sauter, G.; Mihatsch, M.J.; Singer, G. Epithelial growth factor receptor status in primary and recurrent ovarian cancer. Mod Pathol 2006, 19(4), 607-610.
6. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; Santoro, A.; Bets, D.;Mueser,M.; Harstrick, A.; Verslype, C.; Chau, I.; Van Cutsem, E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351(4), 337-345. (Pubitemid 38944402)
7. J̈anne, P.A.; Engelman, J.A.; Johnson, B.E. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 2005, 23(14), 3227-3234.
8. Normanno, N.; De Luca, A.; Bianco, C.; Strizzi, L.; Mancino, M.; Maiello, M.R.; Carotenuto, A.; De Feo, G.; Caponigro, F.; Salomon, D.S. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 366(1), 2-16. (Pubitemid 43199589)
9. Alroy, I.; Yarden, Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997, 410(1), 83-86.
10. Fischer, O.M.; Hart, S.; Gschwind, A.; Ullrich, A. EGFR signal transactivation in cancer cells. Biochem Soc Trans 2003, 31(6), 1203-1208.
11. Luetteke, N.C.; Qiu, T.H.; Fenton, S.E.; Troyer, K.L.; Riedel, R.F.; Chang, A.; Lee, D.C. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 1996, 126(12), 2739-2750.
12. Abbott, B.D.; Lin, T.M.; Rasmussen, N.T.; Albrecht, R.M.; Schmid, J.E.; Peterson, R.E. Lack of expression of EGF and TGF-alpha in the fetal mouse alters formation of prostatic epithelial buds and influences the response to TCDD. Toxicol Sci 2003, 76(2), 427-436.
13. Xian, C.J.; Zhou, X.F. EGF family of growth factors: essential roles and functional redundancy in the nerve system. Front Biosci 2004, 9, 85-92.
14. Gill, G.N.; Lazar, C.S. Increased phosphotyrosine content and inhibition of proliferation in EGF-treated A431 cells. Nature 1981, 293(5830), 305-307.
15. Filmus, J.; Pollak, M.N.; Cailleau, R.; Buick, R.N. MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem Biophys Res Commun 1985, 128(2), 898-905.
16. Chin, Y.E.; Kitagawa, M.; Kuida, K.; Flavell, R.A.; Fu, X.Y. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol 1997, 17(9), 5328-5337.
17. Tikhomirov, O.; Carpenter, G. Ligand-induced, p38-dependent apoptosis in cells expressing high levels of epidermal growth factor receptor and ErbB-2. J Biol Chem 2004, 279(13), 12988-12996.
18. Worthylake, R.; Wiley, H.S. Structural aspects of the epidermal growth factor receptor required for transmodulation of erbB-2/neu. J Biol Chem 1997, 272(13), 8594-8601.
19. Chang, H.W.; Kim, S.Y.; Yi, S.L.; Son, S.H.; Song, do Y.; Moon, S.Y.; Kim, J.H.; Choi, E.K.; Ahn, S.D.; Shin, S.S.; Lee, K.K.; Lee, S.W. Expression of Ku80 correlates with sensitivities to radiation in cancer cell lines of the head and neck. Oral Oncol 2006, 42(10), 979-986.
20. Armstrong, D.K.; Kaufmann, S.H.; Ottaviano, Y.L.; Furuya, Y.; Buckley, J.A.; Isaacs, J.T.; Davidson, N.E. Epidermal growth factor-mediated apoptosis of MDA-MB-468 human breast cancer cells. Cancer Res 1994, 54(20), 5280-5283.
21. Cao, L.; Yao, Y.; Lee, V.; Kiani, C.; Spaner, D.; Lin, Z.; Zhang, Y.; Adams, M.E.; Yang, B.B. Epidermal growth factor induces cell cycle arrest and apoptosis of squamous carcinoma cells through reduction of cell adhesion. J Cell Biochem 2000, 77(4), 569-583.
22. Henson, E.S.; Gibson, S.B. Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell Signal 2006, 18(12), 2089-2097.
23. Wheatley-Price, P.; Shepherd, F.A. Epidermal growth factor receptor inhibitors in the treatment of lung cancer: reality and hopes. Curr Opin Oncol 2008, 20(2), 162-175.
24. Di Fiore, P.P.; Pierce, J.H.; Kraus, M.H.; Segatto, O.; King, C.R.; Aaronson, S.A. ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987, 237(4811), 178-182.
25. Di Marco, E.; Pierce, J.H.; Fleming, T.P.; Kraus, M.H.; Molloy, C.J.; Aaronson, S.A.; Di Fiore, P.P. Autocrine interaction between TGF alpha and the EGF-receptor: quantitative requirements for induction of the malignant phenotype. Oncogene 1998, 4(7), 831-838.
26. Salomon, D.S.; Brandt, R.; Ciardiello, F.; Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995, 19(3), 183-232.
27. Arpino, G.; Green, S.J.; Allred, D.C.; Lew, D.; Martino, S.; Osborne, C.K.; Elledge, R.M. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004, 10(17), 5670-5676.
28. Hudelist, G.; K̈ ostler, W.J.; Czerwenka, K.; Kubista, E.; Attems, J.; M̈ uller, R.; Gschwantler-Kaulich, D.; Manavi, M.; Huber, I.; Hoscḧutzky, H.; Zielinski, C.C.; Singer, C.F. Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumabbased therapy in patients with metastatic breast cancer. Int J Cancer 2006, 118(5), 1126-1134.
29. Pinter, F.; Papay, J.; Almasi, A.; Sapi, Z.; Szabo, E.; Kanya, M.; Tamasi, A.; Jori, B.; Varkondi, E.; Moldvay, J.; Szondy, K.; Keri, G.; Dominici, M.; Conte, P.; Eckhardt, S.; Kopper, L.; Schwab, R.; Petak, I. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. J Mol Diagn 2008, 10(2), 160-168.
30. Helfrich, B.A.; Raben, D.; Varella-Garcia, M.; Gustafson, D.; Chan, D.C.; Bemis, L.; Coldren, C.; Bar ́on, A.; Zeng, C.; Franklin, W.A.; Hirsch, F.R.; Gazdar, A.; Minna, J.; Bunn, P.A. Jr. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res 2006, 12(23), 7117-7125.
31. Raymond, E.; Faivre, S.; Armand, J.P. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000, 60(2), 15-23.
32. Ono, M.; Hirata, A.; Kometani, T.; Miyagawa, M.; Ueda, S.; Kinoshita, H.; Fujii, T.; Kuwano, M. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/ extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol Cancer Ther 2004, 3(4), 465-472.
33. O-charoenrat, P.; Modjtahedi, H.; Rhys-Evans, P.; Court, W.J.; Box, G.M.; Eccles, S.A. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res 2000, 60(4), 1121-1128. (Pubitemid 30129555)
34. Lee, K.F.; Simon, H.; Chen, H.; Bates, B.; Hung, M.C.; Hauser, C. Requirement for neuregulin receptor erbB2 in neural and cardiac development. Nature 1995, 378(6555), 394-398.
35. Stoscheck, C.M.; Carpenter, G. Characterization of the metabolic turnover of epidermal growth factor receptor protein in A-431 cells. J Cell Physiol 1984, 120(3), 296-302. (Pubitemid 14054456)
36. Sorkin, A.; Goh, L.K. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 2008, 314(17), 3093-3106.
37. Nishimura, Y.; Yoshioka, K.; Bereczky B.; Itoh, K. Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line. Mol Cancer 2008, 7, 42.